These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 24034380)

  • 1. Kawasaki disease: part II. Complications and treatment.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC; Aronoff SC
    Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
    Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kawasaki disease: part I. Diagnosis, clinical features, and pathogenesis.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):501.e1-11; quiz 511-2. PubMed ID: 24034379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Kawasaki disease: what you need to know].
    Bajolle F; Laux D
    Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM; McCrindle BW; Silverman ED; Tyrrell PN; Wong J; Yeung RS
    Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y; Wang XM; Liu YL; Shi K; Yang YF; Guo YH
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Harada score in the US population of children with Kawasaki disease.
    Tewelde H; Yoon J; Van Ittersum W; Worley S; Preminger T; Goldfarb J
    Hosp Pediatr; 2014 Jul; 4(4):233-8. PubMed ID: 24986993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kawasaki disease.
    Scuccimarri R
    Pediatr Clin North Am; 2012 Apr; 59(2):425-45. PubMed ID: 22560578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of acute and refractory Kawasaki disease.
    Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kawasaki disease.
    Sundel RP
    Rheum Dis Clin North Am; 2015; 41(1):63-73, viii. PubMed ID: 25399940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Kawasaki disease: clinical characteristics and cardiovascular involvement in a cohort of 121 patients].
    Calabri GB; Falcini F; Favilli S; Pollini I; Capuzzo L; Simonini G; De Simone L
    Pediatr Med Chir; 2002; 24(5):352-7; discussion 397-9. PubMed ID: 12494535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.